This Article is no longer available, this page is showing similar articles.

Food, Drugs, Healthcare, Life Sciences

Subscribe

Welcome to the Mondaq Food, Drugs, Healthcare, Life Sciences homepage, here you will find thought leadership articles, podcasts, videos and webinars providing insights covering topics such as Food and Drugs Law, Healthcare, Life Sciences, Biotechnology and Nanotechnology.

CMS Proposes Significant Medicare Advantage Payment And Compliance Changes For 2027

The Centers for Medicare & Medicaid Services (CMS) has issued its Advance Notice and related rulemaking for the Medicare Advantage (MA) and Part D programs for plan year 2027.

United States Healthcare

CH

Clark Hill

Teva Receives FDA Approval Of Denosumab Biosimilar And Filing Acceptances By FDA And EMA For Omalizumab Biosimilar

On March 30, 2026, Teva Pharmaceutical Industries Ltd. ("Teva") announced that the U.S. Food and Drug Administration ("FDA") has approved its denosumab biosimilar, PONLIMSI™ (denosumab-adet).

United States Healthcare

GP

Goodwin Procter LLP

A Hard Pill To Swallow: 100% Tariffs Hit Pharma

While Section 232 tariffs have so far been largely a metals-and-autos story, pharma has now officially joined the narrative.

United States Healthcare

AF

ArentFox Schiff

FTC Mandates Point-of-Sale Rebates For Prescription Drugs

The Federal Trade Commission (FTC) recently issued a Decision and Order directed at certain pharmacy benefit managers (PBMs). Although the order specifically applies to Express Scripts, Evernorth Health, Medco...

United States Healthcare

HB

Hall Benefits Law

Cosmetics Under The Microscope: FDA’s Expanding Regulatory Reach Under MoCRA

United States Healthcare

CM

Crowell & Moring LLP

Amgen And Shanghai Henlius/Organon Settle Denosumab BPCIA Litigation

United States Healthcare

GP

Goodwin Procter LLP

Federal And State Policymakers Push Forward With PBM And Drug Pricing Reform Even In The Wake Of Sweeping Actions Earlier This Year

United States Healthcare

M

Mintz

Nursing Home Fraud One Of Many Targets Of DOJ Enforcement Division

United States Healthcare

RB

Reinhart Boerner Van Deuren s.c.

FDA Dives Deeper Into The Use Of Digital Health Technologies In Drug Development With New RFI

United States Healthcare

AG

Akin Gump Strauss Hauer & Feld LLP

From Hype To Execution: Scaling Health Tech Platforms (Podcast)

United States Healthcare

SR

McDermott Will & Schulte

A Tough Dose: 100% Tariffs Target Foreign-Manufactured Brand-Name Pharmaceuticals

United States Healthcare

JD

Jones Day

CMS Finalizes CY 2027 Medicare Advantage And Part D Rule

United States Healthcare

HK

Holland & Knight

Upcoming ASM Payment Model Changes Impact Healthcare Lenders

United States Healthcare

HK

Holland & Knight

Podcast - Why Recall Planning Matters For Every Food Company

United States Healthcare

HK

Holland & Knight

See more

Webinars

See More

Recorded on 20 Jan 2026 | 3:00 PM

2026 Canadian In-House Counsel Report: Unparalleled Insights into Canada's In-House Profession from CBA In-House Lawyers

TC

CBA In-House Lawyers

Recorded on 24 Jun 2025 | 3:00 PM

(2nd Session) 2025 Global In-House Counsel Survey Report: Unique Insights into the Global In-House Counsel Profession

IC

In-House Counsel Worldwide

Recorded on 24 Jun 2025 | 9:00 AM

(1st Session) 2025 Global In-House Counsel Survey Report: Unique Insights into the Global In-House Counsel Profession

IC

In-House Counsel Worldwide

Recorded on 30 Apr 2025 | 2:00 PM

Mondaq | 2025 Law Firm Data Landscape Report

mm

Mondaq

Highlighted Content

Plausibility At The EPO – An Update On G2/21

United States Healthcare

D

Dehns

Infringement Of Repurposed Drug Patents And Skinny Labelling – Where Does The Balance Lie In The United States Today?

United States Healthcare

D

Dehns

Infringement Of Repurposed Drug Patents And Skinny Labelling – Where Does The Balance Lie In Europe Today?

United States Healthcare

D

Dehns

How Good Does A Copy Need To Be?

United States Healthcare

D

Dehns

Supplementary Protection Certificates – European Patent Term Extensions

United States Healthcare

D

Dehns

How Much Experimental Data Is Needed For Patent Applications In Europe?

United States Healthcare

D

Dehns

The Silent Treatment: The EPO's Approach To Non-therapeutic Methods Encompassing Therapeutic Effects

United States Healthcare

D

Dehns

Implications Of The Genetic Technology (Precision Breeding) Bill On The Life Science IP Sector

United States Healthcare

D

Dehns

Protection For Plant Varieties In Europe And The UK Post-Brexit

United States Healthcare

D

Dehns

Best Practice For Invention Harvesting

United States Healthcare

D

Dehns

Healthcare

Industry Voices—Hospitals Are Fueling AI Innovation, Should They Own A Piece Of It?

What does a “fair” partnership between hospitals and AI developers look like? As hospital workflows, clinician expertise, and rich clinical data increasingly fuel the performance and market value of vendors’ AI tools, providers face a critical question...

United States Technology

SM

Sheppard, Mullin, Richter & Hampton LLP

A Hard Pill To Swallow: 100% Tariffs Hit Pharma

While Section 232 tariffs have so far been largely a metals-and-autos story, pharma has now officially joined the narrative.

United States Healthcare

AF

ArentFox Schiff

Hemp Product Use In Medicare: CMS Greenlights Pilot Program Under The Substance Access Beneficiary Engagement Incentive

On April 1, 2026, the Centers for Medicare & Medicaid Services (CMS), through the CMS Innovation Center (CMMI), officially launched a new pilot program which allows participants in specific CMS programs to offer eligible hemp products to eligible Medicare beneficiaries.

United States Cannabis

FL

Foley & Lardner

CMS Proposes Significant Medicare Advantage Payment And Compliance Changes For 2027

United States Healthcare

CH

Clark Hill

ERISA Preemption – Alive And Well

United States Employment

BB

Bass, Berry & Sims

FTC Mandates Point-of-Sale Rebates For Prescription Drugs

United States Healthcare

HB

Hall Benefits Law

Cosmetics Under The Microscope: FDA’s Expanding Regulatory Reach Under MoCRA

United States Healthcare

CM

Crowell & Moring LLP

Federal And State Policymakers Push Forward With PBM And Drug Pricing Reform Even In The Wake Of Sweeping Actions Earlier This Year

United States Healthcare

M

Mintz

Nursing Home Fraud One Of Many Targets Of DOJ Enforcement Division

United States Healthcare

RB

Reinhart Boerner Van Deuren s.c.

See more

Food and Drugs Law

New Advertising Code For Food Products

As of 1 February 2026, stricter rules apply to advertising food products aimed at children and young people. The revised Advertising Code for Food Products (RVV 2026) has now entered into force.

United States Media & IT

GA

Global Advertising Lawyers Alliance (GALA)

A Hard Pill To Swallow: 100% Tariffs Hit Pharma

While Section 232 tariffs have so far been largely a metals-and-autos story, pharma has now officially joined the narrative.

United States Healthcare

AF

ArentFox Schiff

Teva Receives FDA Approval Of Denosumab Biosimilar And Filing Acceptances By FDA And EMA For Omalizumab Biosimilar

On March 30, 2026, Teva Pharmaceutical Industries Ltd. ("Teva") announced that the U.S. Food and Drug Administration ("FDA") has approved its denosumab biosimilar, PONLIMSI™ (denosumab-adet).

United States Healthcare

GP

Goodwin Procter LLP

ERISA Preemption – Alive And Well

United States Employment

BB

Bass, Berry & Sims

FTC Mandates Point-of-Sale Rebates For Prescription Drugs

United States Healthcare

HB

Hall Benefits Law

Cosmetics Under The Microscope: FDA’s Expanding Regulatory Reach Under MoCRA

United States Healthcare

CM

Crowell & Moring LLP

Massachusetts Court Narrows One Chip Challenge Lawsuit At Motion To Dismiss Stage

United States Consumer

GT

Greenberg Traurig, LLP

Federal And State Policymakers Push Forward With PBM And Drug Pricing Reform Even In The Wake Of Sweeping Actions Earlier This Year

United States Healthcare

M

Mintz

Nursing Home Fraud One Of Many Targets Of DOJ Enforcement Division

United States Healthcare

RB

Reinhart Boerner Van Deuren s.c.

See more

Life Sciences, Biotechnology & Nanotechnology

A Hard Pill To Swallow: 100% Tariffs Hit Pharma

While Section 232 tariffs have so far been largely a metals-and-autos story, pharma has now officially joined the narrative.

United States Healthcare

AF

ArentFox Schiff

CMS Proposes Significant Medicare Advantage Payment And Compliance Changes For 2027

The Centers for Medicare & Medicaid Services (CMS) has issued its Advance Notice and related rulemaking for the Medicare Advantage (MA) and Part D programs for plan year 2027.

United States Healthcare

CH

Clark Hill

Amgen And Shanghai Henlius/Organon Settle Denosumab BPCIA Litigation

On March 31, 2026, the District Court for the District of New Jersey entered a Consent Order and Judgment in the BPCIA litigation Amgen brought against Henlius...

United States Healthcare

GP

Goodwin Procter LLP

Regulatory Horizons: Supply Chain Sovereignty: How U.S. And EU Regulatory Priorities Are Reshaping Life Sciences Manufacturing (Podcast)

United States Healthcare

B

BakerHostetler

Ohio Legislatures Sign PBM Reform Into Law

United States Healthcare

BI

Buchanan Ingersoll & Rooney PC

Trade Winds Shift For Pharma: Understanding The Section 232 Tariff Proclamation On Pharmaceuticals

United States International

AP

Arnold & Porter

Trump Administration Announces Tariffs On Imported Patented Medication And Pharmaceutical Ingredients Under Section 232 Of The Trade Expansion Act Of 1962

United States International

MB

Mayer Brown

FDA Presses Forward On Incorporating Patient Preferences In Device Decision Making, Releases Updated Final Guidance

United States Healthcare

AG

Akin Gump Strauss Hauer & Feld LLP

The Brain-Computer Interface Race Is On – Is The Law Ready?

United States Healthcare

AF

ArentFox Schiff

See more

Latest Videos

See more

PBM Reform 2026: What Recent Legislation Means For The Industry (Video)

M

Mintz

In The Know: The Clean Beauty Trend Becomes State Law (Video)

LL

Loeb & Loeb LLP

GT Legal Food Talk Episode 30: Navigating Liquor Licensing: Inside The Legal Food & Beverage Landscape (Podcast)

GT

Greenberg Traurig, LLP

Leaders In Law: Life Sciences And Technology Transactions With Jekkie Kim (Podcast)

W

WilmerHale

Digging Into New York's New Price-Gouging Rules (Video)

BS

Bond, Schoeneck & King PLLC

Upcoming Events

Speaking Engagement

30th Annual Compliance Institute

United States Healthcare

W

WilmerHale

Competition Bootcamp: Webinar For In-House Life Sciences Lawyers

United States Healthcare

AP

Arnold & Porter

Health Tech Investment Forum 2026

United States Healthcare

SR

McDermott Will & Schulte

Peptides Under The Microscope: Regulation, Enforcement, And Market Implications

United States Healthcare

SR

McDermott Will & Schulte

NC ASHRM 2026 Spring Conference

United States Healthcare

YM

Young Moore and Henderson

17th Annual Advanced Forum On Managed Care Disputes And Litigation

United States Healthcare

BB

Bass, Berry & Sims

Asembia’s AXS26 Summit

United States Healthcare

SR

McDermott Will & Schulte

Doing Life Sciences Deals In 2026 — Licensing, M&A, China, And More

United States Healthcare

M

Mintz

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More